Next 10 |
-- Povetacicept demonstrates greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion -- -- Povetacicept exhibits greater distribution to disease-related end organs compared with WT TACI-Ig -- -- A phase 2 study in SLE (DENALI) ...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2 nd Annual Autoimmune & Inflammator...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved 15.08% on the day to $40.82. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunothera...
A look at the top 10 most actives in the United States Ontrak Inc. (OTRK) rose 214.5% to $0.5975 on volume of 79,666,583 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $3.7703 on volume of 36,416,698 shares Enveric Biosciences Inc. (ENVB) rose 35.5% to $1.49 on vol...
2024-03-18 19:24:06 ET Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Results Conference Call March 18, 2024 04:30 PM ET Company Participants Temre Johnson - Senior Director, Investor Relations and Corporate Communications Mitchell Gold - Executive Chairman and Chief Ex...
2024-03-18 16:38:49 ET Gainers: National CineMedia ( NCMI ) +8% . Inventiva ( IVA ) +6% . Alpine Immune Sciences ( ALPN ) +5% . Leslie's ( LESL ) +5% . Maxeon Solar Technologies ( MAXN ) +5% . Losers: DLocal ( DLO...
2024-03-18 16:15:47 ET More on Alpine Immune Sciences Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade) Alpine Immune Sciences Q4 2023 Earnings Preview Wolfe ...
-- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
2024-03-17 17:35:21 ET Major earnings expected after the bell on Monday include: StoneCo Ltd. ( STNE ) JOYY ( YY ) Bit Digital ( BTBT ) Xiaomi Corporation ( OTCPK:XIACF ) DLocal Limited ( DLO ) Read the full article on Seeking Alpha Fo...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
-- Povetacicept demonstrates greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion -- -- Povetacicept exhibits greater distribution to disease-related end organs compared with WT TACI-Ig -- -- A phase 2 study in SLE (DENALI) ...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2 nd Annual Autoimmune & Inflammator...
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS...